Some studies demonstrated that the use of IL-6 blocking agents reduced the risk of poor outcomes and secondary infection in hospitalized COVID-19 patients and was linked to decreased 28-day all-cause mortality and a shorter hospital stay [44–46]. This evidence concerns the gene IL6 and COVID-19.